Carborane-based design of a potent vitamin D receptor agonist

Area of Science:

• Oncology
• Medicinal Chemistry
• Molecular Biology

Background:

• The vitamin D nuclear receptor (VDR) is a promising target for cancer therapy due to its expression in tumors and the anticancer actions of its ligands.
• Boron neutron capture therapy (BNCT) is an emerging cancer treatment modality.

Purpose of the Study:

• To design and synthesize a novel VDR agonist for potential cancer therapy, combining VDR targeting with BNCT applications.
• To create a secosteroidal analog incorporating an o-carborane moiety for enhanced VDR interaction and therapeutic efficacy.

Main Methods:

• Synthesis of a novel secosteroidal VDR agonist containing an o-carborane unit.
• Transcriptional assays to evaluate VDR agonist activity and potency compared to 1α,25-dihydroxyvitamin D3 (1,25D).
• Assessment of antiproliferative, pro-differentiating, and hypercalcemic activities.
• Crystal structure determination of the VDR-ligand complex.

Main Results:

• The synthesized ligand is the first secosteroidal analog with a carborane unit that efficiently binds to VDR and acts as an agonist with 1,25D-like potency.
• The compound demonstrated similar antiproliferative and pro-differentiating effects as 1,25D but was significantly less hypercalcemic.
• Crystal structure analysis revealed boron-mediated dihydrogen bonds in the VDR binding mechanism, mimicking natural vitamin D interactions.

Conclusions:

• This novel carborane-containing vitamin D analog is a potent VDR agonist with therapeutic potential for cancer treatment, offering reduced hypercalcemia.
• The study provides a foundation for designing new vitamin D analogs with carborane moieties for molecular recognition and drug development.